Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
REGN News
Insiders have been trading these 5 stocks: ((BX)), ((REGN)), ((SCHW)), ((TSE:CLS)) and ((GLW)). Here is a breakdown of their recent trades and their value. Elev...
In the past week, OPKO Health announced a major research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies, while also reporting...
Regeneron Pharmaceuticals (REGN) stock has climbed around 17% in the past 3 months, despite some volatility this year. Investors are watching to see if recent t...
Analyst ratings
76%
of 29 ratingsMore REGN News
Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Inv...
Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 5...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at...
RBC Capital raised the firm’s price target on Regeneron (REGN) to $708 from $704 and keeps a Sector Perform rating on the shares after its Q3 earnings beat. The...
If you find yourself pausing over Regeneron Pharmaceuticals this week, you are definitely not alone. With the stock surging 13.0% in just the last seven days an...
In a report released today, Tim Anderson from Bank of America Securities reiterated a Sell rating on Regeneron, with a price target of $627.00. Elevate Your Inv...